Editorial: New Trends and Approaches in Perioperative Pharmacotherapy: An Update

S. Soghomonyan1*, N. Stoicea2 and S. D. Bergese3

1Department of Anesthesiology, Ohio State University Wexner Medical Center, Columbus, OH, United States, 2Ohio State University College of Pharmacy, Columbus, Summa Health System, Akron, OH, United States, 3Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States

Keywords: perioperative pharmacotherapy, postoperative recovery, anesthesia, adverse drug effects, enhanced recovery after anaesthetic, postoperative nausea and vomiting

Editorial on the Research Topic

New Trends and Approaches in Perioperative Pharmacotherapy: An Update

The perioperative period poses significant additional risks on patients, who already suffer from various health-related problems. Even with advances in surgical treatment, anesthesia safety, diagnostic imaging, and intensive care, the perioperative period is still associated with serious morbidity and mortality. According to Bhatia et al. (2021), the 30-day mortality in patients undergoing non-cardiac surgery remains as high as 1.3–1.9%, and the incidence of postoperative myocardial infarction reaches 4.2–6.3%. Cerebrovascular and pulmonary complications, impaired glycemic control, metabolic derangement, infections, and iatrogenic complications all add up to the long list of potential risks and adverse effects encountered in the perioperative period (Ben-Shlomo and Melmed, 2003). Current approaches to perioperative patient care highlight the requirement for adequate pain control using multimodal therapy: opioids, non-opioid analgesics, gabapentinoids, pain modifiers, regional blocks, and other therapies. Post-surgical enhanced recovery protocols have been developed in recent years allowing for shortened recovery time and improved patient satisfaction.

Patients undergoing surgery commonly receive chronic treatment with anti-hypertensives, anti-arrhythmic drugs, anticoagulants, chemotherapeutic drugs, and other medications. Many of these drugs have the potential to cause serious drug-drug interactions and perioperative adverse effects (Pai et al., 2017; Pfeifer et al., 2021).

Undoubtedly, questions related with the perioperative patient care and drug management in this patient group are among the most discussed in medical literature. The Society for Perioperative Assessment and Quality Improvement highlights the importance of evidence-based approach to perioperative care and medication management (Pfeifer et al., 2021). Current approaches to perioperative patient care highlight the requirement for adequate pain control using multimodal therapy: opioids, non-opioid analgesics, gabapentinoids, pain modifiers, regional blocks, and other therapies. Post-surgical enhanced recovery protocols have been developed in recent years allowing for shortened recovery time and improved patient satisfaction.

The current update of our topic is an attempt to put together the recent advances in the field of perioperative pharmacotherapy and present opinions and results of health care professionals from different hospitals and countries.

The manuscripts that were included in the topic cover several important aspects of patient care. Questions discussed include drug interactions and adverse drug reactions during anesthesia, coagulation management in patients undergoing liver transplant surgery, interaction of cigarette smoking and drugs used during anesthesia, efficacy of antifibrinolytic...
therapy in major spinal surgery, use of vasopressors in free tissue transfer in head and neck surgery, and many other important problems.

The efficacy of prevention and treatment of postoperative nausea and vomiting (PONV) is an important component of perioperative care and one of the criteria to assess quality of care. It is well known that many drugs used in PONV management prolong the QTc on the EKG. However, there are insufficient data in literature related to PONV management in patients who present with an already prolonged QTc. A mini-review in our topic presents this important question attempting to focus the attention of clinicians and researchers on this important problem and encouraging further discussion and research to find an optimal strategy for PONV management in this patient category.

As a conclusion, surgery and anesthesiology are actively changing disciplines, and effective treatment of patients undergoing surgery is only possible with an up-to-date knowledge of the ongoing trends and advances in perioperative pharmacotherapy.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**REFERENCES**

Ben-Shlomo, A., and Melmed, S. (2003). The Role of Pharmacotherapy in Perioperative Management of Patients with Acromegaly. *J. Clin. Endocrinol. Metab.* 88 (3), 963–968. PMID: 12629068. doi:10.1210/jc.2002-020072

Bhatia, K., Narasimhan, B., Aggarwal, G., Hajra, A., Itagi, S., Kumar, S., et al. (2021). Perioperative Pharmacotherapy to Prevent Cardiac Complications in Patients Undergoing Noncardiac Surgery. *Expert Opin. Pharmacother.* 22 (6), 755–767. Epub 2020 Dec 31. PMID: 33350868. doi:10.1080/14656566.2020.1856368

Pai, S. L., Chadha, R. M., Irizarry-Alvarado, J. M., Renew, J. R., and Aniskevich, S. (2017). Pharmacologic and Perioperative Considerations for Antihypertensive Medications. *Curr. Clin. Pharmacol.* 12 (3), 135–140. PMID: 28925860. doi:10.2174/1574884712666170918152004

Pfeifer, K. J., Selzer, A., Mendez, C. E., Whinney, C. M., Rogers, B., Simha, V., et al. (2021). Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. *Mayo Clinic Proc.* 96 (20), 1655–1669. Epub ahead of print. PMID: 33714600. doi:10.1016/j.mayocp.2020.10.002

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Soghomonyan, Stoica and Bergese. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.